Johnson & Johnson Vision Announces Availability of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management in Singapore

  • Breakthrough daily-wear lens was specifically designed for slowing the progression of myopia in children,1 the biggest eye health threat of the 21st century.2
  • Singapore is the second market in Asia Pacific, along with Hong Kong, to offer both Abiliti Overnight lenses and Abiliti 1-Day lenses.

SINGAPORE – December 8, 2022 – Johnson & Johnson Vision,* a global leader in eye health and part of Johnson & Johnson MedTech,** announced today the availability of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management in Singapore. The daily wear, single-use, disposable lens has the potential to slow the progression of myopia in children who are 7 to 12 years old at the start of treatment.***1,3 Abiliti 1-Day is part of Johnson & Johnson Vision’s comprehensive approach for myopia management, including Abiliti Overnight Therapeutic Lenses for Myopia Management, an orthokeratology (ortho-K) lens, which received CE mark for myopia control in Singapore earlier this year.

“Myopia is often referred to as nearsightedness, but we know it is so much more than that — it is the biggest threat to eye health of the 21st century,2 and in Singapore alone, eight out of 10 children are likely to be myopic by Primary Six,4” said Vaibhav Saran, Area Vice President, Johnson & Johnson Vision, Asia Pacific.**** “Young children who develop myopia before the age of 12 are at greater risk of developing high myopia, making them more vulnerable to vision complications later in life.5 That is why it is imperative that we not only control the symptoms of myopia, but also provide solutions that have the potential to slow its progression in children,1 like Abiliti 1-Day.”

Abiliti 1-Day lenses are not traditional concentric ring dual focus lenses1 they are a breakthrough innovation specifically designed to slow myopia progression in children, and have been shown to reduce axial elongation by 0.105mm on average over a 6-month period.*****6 The lenses are built from silicone hydrogel (senofilcon A) lens material, the same material as ACUVUE® OASYS® 1-Day contact lenses, which have never been beaten in comfort.1,7

Singapore is the second market in Asia Pacific, along with Hong Kong, to offer both Abiliti Overnight lenses and Abiliti 1-Day lenses. Among the first in the industry to recognize the impact of myopia and the importance of myopia management, Johnson & Johnson Vision launched the Abiliti brand to address the prevalence and progression of myopia in children. Abiliti is a holistic suite of myopia management solutions designed to fit seamlessly into the lifestyle of parents and children. This includes the Abiliti Overnight lens, successfully prescribed for controlling the progression of myopia in children as young as six years of age, the SeeAbiliti™ personalized digital companion app designed to support kids and parents in their myopia management journey, and now the Abiliti 1-Day lens.

Additionally, each annual purchase of an Abiliti product will provide a free comprehensive eye health exam to a child in need through Sight For Kids – a program co-founded by Johnson & Johnson Vision and Lions Clubs International Foundation. Sight For Kids is one of the largest-known, school-based eye health programs that mobilizes Lions and eye care professionals to provide comprehensive eye health services in low-income schools around the world.

Families and eye care professional who want more information can visit


About Johnson & Johnson Vision

At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.comfollow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson MedTech

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

About ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses

ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management are intended for daily wear, worn on a daily disposable basis, for the correction of myopia (while the lenses are worn) and may slow myopia progression in children. The contact lenses are intended to be used by children who, at the initiation of treatment, are 7 to 12 years old, with myopia between -0.75D and -4.50D and 1.00D or less astigmatism, with non-diseased eyes and are symptomatic with regard to a need for distance vision correction. Slowing axial elongation and myopia progression was demonstrated in a clinical study of children between 7 and 12 years of age with a required lens wear time of, at a minimum, 8 hours per day and 5 days per week.***** Longer-term myopia control effect of the lens as well as permanent myopia control after lens treatment is discontinued has not been established through clinical trials.

About Abiliti ™ Overnight Therapeutic Lenses

Abiliti™ Overnight Therapeutic Lenses are CE-marked overnight ortho-K therapeutic lens that is scientifically proven to reduce the axial elongation by 0.28mm on average over 2 years.*8,9,10,11 Worn overnight, these lenses temporarily reshape the cornea12,13,14,15 and allow patients to see clearly the next day after being worn overnight.**16 Each lens is specifically designed to fit the unique shape of each patient's unique corneal shape and prescription.17 Abiliti™ Overnight Lenses can help manage the progression of your child's myopia.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Vision, any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


1 JJV Data on File, 2021. Development of Optical Design of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management.
2 JJV Data on File, 2020. Myopia Compendium.
3 JJV Data on File, 2021. Mechanical Design of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management- Effect on Fit and Handling.
4 The Straits Times. Don’t be short-sighted about myopia in children. Available at care/Don%E2%80%99t-be-short-sighted-about-myopia-in-children. Last accessed December 2021.
5 Hu Y et al. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020;138:1–6.
6 JV Data on File, 2021. Efficacy of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management: Comparative Claims vs. Single Vision and Dual Focus Lenses.
7 is a website maintained by the NIH. The 27 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUE OASYS Brand 2-week family, ACUVUE OASYS 1-Day Brand family, and ACUVUE OASYS MAX 1-Day Brand family of contact lenses, vs. competitors’ products. Review conducted as of October 31, 2022.
8 Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci [Internet]. 2012/09/13. 2012;53(11):7077– 85.
9 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez- Ortega R. Myopia control with orthokeratology contact lens in Spain: Refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012;53(8).
10 Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci [Internet]. 2013/09/05. 2013;54(10):6510–7.
11 Walline JJ, Robboy MW, Hilmantel G, Tarver ME, Afshari NA, Dhaliwal DK, Morse CL, Quinn CJ, Repka MX, Eydelman MB. Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association, American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co- Sponsored Workshop: Controlling the Progression of Myopia: Contact Lens and Future Medical Devices. Eye Contact Lens.
12 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez- Ortega R. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40(2).
13 Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye [Internet]. 2017/01/01. 2017;40(2):82–7.
14 Lau JK, Vincent SJ, Cheung SW, Cho P. The influence of orthokeratology compression factor on ocular higher-order aberrations. Clin Exp Optom. 2020 Jan; 103(1):123-128
15 Wan K, Lau JK kit, Cheung SW, Cho P. Refractive and corneal responses of young myopic children to short-term orthokeratology treatment with different compression factors. Contact Lens Anterior Eye. 2020;43(1):65-72.
16 Data on File 2021. Menicon CE technical file.
17 Data on File 2021 Menicon Design History file.
**Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
***Utilizing a smaller lens diameter designed to fit the smaller anatomical features of a pediatric population children (aged 7-12).
**** Vaibhav Saran is an employee of Johnson & Johnson Vision Care, Inc., serving as Area Vice President in Asia Pacific.
*****Compared to single vision contact lenses after 6 months wear.

© Johnson & Johnson Vision Care, Inc. 2022. All rights reserved.